HNNA vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HNNA exhibits a strong deterministic health profile with a Piotroski F-Score of 8/9 and a negligible debt-to-equity ratio of 0.01, indicating a pristine balance sheet. While the stock is significantly undervalued relative to its Graham Number ($18.01) and trades at a low P/E of 8.61, this value is offset by alarming growth trends, with revenue and earnings declining by 14.3% and 33.3% respectively. The company functions as a high-yield value play with a sustainable 6.06% dividend, but lacks a catalyst for price appreciation given the bearish technical trend and negative growth trajectory.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
HNNA vs JPM: Head-to-Head Comparison
This page compares Hennessy Advisors, Inc. (HNNA) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.